Drug Profile
CK 0801
Alternative Names: CK-0801Latest Information Update: 04 Jul 2023
Price :
$50
*
At a glance
- Originator Cellenkos; University of Texas M. D. Anderson Cancer Center
- Developer Cellenkos; University of Texas Health Science Center at Houston; University of Texas M. D. Anderson Cancer Center
- Class T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Bone marrow disorders
- Preclinical Guillain-Barre syndrome
- No development reported Autoimmune disorders; Graft-versus-host disease; Multiple sclerosis; Psoriasis
- Discontinued Type 1 diabetes mellitus